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Tolerance and Efficacy of Amphotericin B 
Inhalations for Prevention of Invasive Pulmonary 
Aspergillosis in Haematological Patients
Z. Erjavec1*, G.M.H. Woolthuis4, H.G. de Vries-Hospers2, W.J. Sluiter3, 
S.M.G.J. Daenen1, B. de Pauw5, M.R. Halie1
The tolerance of aerosolised amphotericin B as prophylaxis against invasive pulmonary 
aspergillosis was investigated in 61 granulocytopenic periods in 42 patients treated for 
a haematologic malignancy. Each patient was to receive amphotericin B in doses es­
calating to 10 mg three times daily (t.i.d.), but only 20 (48%) patients managed to com­
plete the scheduled regimen. One patient tolerated the full dose initially, but had to dis­
continue treatment when dyspnea developed as a result of pneumonia and acute re­
spiratory distress. Another 22 patients (52%) experienced side effects, including eight 
(19%) who reported mild coughing and dyspnea but who tolerated the full dose and three 
(7%) patients whose dose was reduced to 5 mg t.i.d. Another six (14%) patients could 
tolerate only 5 mg t.i.d., and five (12%) others stopped treatment because of intoler­
ance. Elderly patients (p < 0.05) and those with a history of chronic pulmonary obstruc­
tive disease (p = 0.09) were more likely to develop side effects during inhalation. Twelve 
(28%) patients developed proven or possible invasive fungal infections, but no correla­
tion was established between infection and the total amount of amphotericin B inhaled. 
Inhalation of aerosolised amphotericin B is poorly tolerated and does not appear use­
ful in preventing invasive pulmonary aspergillosis in granulocytopenic patients.
Hie use of broad-spectrum antibacterial agents 
has reduced the mortality associated with bacte­
rial infections in granulocytopenic patients, but the 
incidence of invasive fungal infections in these pa­
tients has increased. Today, invasive fungal infec­
tions constitute a major cause of morbidity and 
mortality in patients treated for haematological 
cancer as well as in other immunocompromised 
patients (1). Apart from granulocytopenia and mu­
cositis, other recognised predisposing factors in­
clude treatment with corticosteroids and broad-
Invasive pulmonary aspergillosis (Il'A) is the 
most common form of invasive aspergillosis (3), 
but its diagnosis is difficult to establish at an ear­
ly stage of infection. Consequently, it has beeomo 
common practice to institute empiric therapy 
with amphotericin B for fever unresponsive to an­
tibacterial treatment (4). Prophylaxis may produce 
better results, but parenteral treatment with am­
photericin B is often complicated by side effects 
(5), and the drug is not absorbed when given oral­
ly. Inhalation of aerosolised amphotericin B
spectrum antibiotics and the use of central venous seems to offer an alternative approach to deliver
catheters (2).
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ing the drug to the site of infection (6-10,12, Li), 
but its value has yet to be determined by formal 
randomised clinical trials,since the studies under­
taken thus far have relied on comparison with his­
torical controls (7,9-13).
When the incidence of IPA increased in our de­
partment (14), we investigated the feasibility of ad­
ministering aerosolised amphotericin B to our 
haematological patients. If proven tolerable and 
effective, this formulation would offer a means of
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Table 1: Patient characteristics.
No. of patients (periods of prophylaxis) 42 (61)
No. of females: males 22:20
Median age in years (range) 42 (18-68)
Haematological disorder (periods of prophylaxis)
Acute myeloid leukaemia 22 (33)
Acute lymphocytic leukaemia 17 (25)
Aplastic anaemia 1 (1)
Autologous bone marrow transplantation 1 (1)
Chronic myeloid leukaemia 1 (1)
delivering treatment with amphotericin B without 
the risk of nephrotoxicity and other systemic side
Patients and Methods*
Patients. Foriy«iwo patients admitted to the Department of 
Haematology. University Hospital Groningen, the Nether* 
luiul*. were included consecutively if granulocytopenia (abso­
lute neutrophil count * 5(H) eells/ml} of more than seven days* 
duration was anticipated as a result ot treatment of  their un* 
deriving disease and the patient had given written informed 
consent, Hie study was approved hy the local medical e th ics  
committee, C hem otherapy  for acute myelogenous leukaemia 
(A M L ) or Chronic myelogenous leukaemia (CM L) in m ye­
logenous blast crisis consisted ot a regimen of cytarahine and 
daunorubieine or amsaerine for the first two induction cours­
es; a combination of nu toxantrone and etoposide w as  given 
lor consolidation treatment,  ‘Hie treatment of acute lym pho­
blastic leukaemia (A l  l.) included two courses of predniso* 
lone, adriamvein, and vincristine. Aplastic anaemia was t rea t­
ed with antithymocyte globulin. Cyclophosphamide and total 
body irradiation were given as conditioning treatment for a u ­
tologous bone marrow transplantation. Twelve patients were 
nursed in single rooms equipped with laminair air flow and 
high-efficiency particulate air (H l-PA) filtration, Hie remain ' 
der  were housed in s tandard  rooms, two or more persons to a 
room, without anv air filtration.
a
Sattiv Ik'si^n, Patients were entered  into the study as soon as  
the diagnosis of haematological disorder had been made and 
a trea tm ent had been planned. The starting dose o f a m p h o te r  
icin B was I mg t.i.d.. which was increased every day by I mg 
until 5 mg t.i.d. was attained. The dose was to be increased 
thereafter to Hi mg t.i.d. unless severe side effects occurred m 
which case 5 mg t.i.d. was given. Treatment would continue 
until the granulocytopenia ended  unless signs of bronchial 
obstruction appeared, severe nausea or vomiting occurred, 
less than 5 mg amphotericin B t.i.d could be tolerated, or the 
patient withdrew consent. W hen i.v. amphotericin B was 
deem ed necessarv, inhalations were continued.
*
Delivery o f  Amphotericin IL A sterile solution of 5 mg/ml a m ­
photericin B desoxvcholate was p repared  in 5% glucose and 
diluted in 2 ml sterile w ater  to obtain the desired quantity. 
11ns solution was administered as an aerosol using a Pari- 
InhalerBoy (Pari AVer k G m b H , G erm any),  which produces 
particles of0 .5  to 5.5 microns. This device was chosen because 
it is designed to deliver particles of the desired si*e sufficient­
ly deep  in the bronchial tree (15). Patients were instructed to
inhale amphotericin B solution through a mouthpiece hy in­
haling as deeply as possible and to exale through the nose, 
“Hie procedure took approximately 20 mill.
Selective tint Decontamination, Selective gut decontam ina­
tion was started immediately before cy to reductive treatment 
and consisted of either %() mg cotrimoxa/olc t.i.d. o r  500 mg 
ciprofloxacin b.i.d, In addition, all patients were given 500 mg 
tablets of amphotericin B and 10 m glo /enges  containing the 
drug q.i.d. Cotrimoxazole was replaced by 2(H) mg colistin 
q.i.d. when a patient developed a skin rash.
Empiric Therapy. When fever developed, a thorough physical 
examination was performed, radiographs of the chest and si­
nuses were obtained, and venous blood was drawn for cul­
tures, Patients were then given 5(H) mg imipenem-eilastatin i,v, 
q.i.d. empirically. This regimen was complemented with I 
mg/kg/day amphotericin B i,v. when unexplained fever p e r ­
sisted for more than six days.
( (assification o f  Aspergillosis. For aspergillosis to he consid­
ered proven, histologic evidence of hyphae invasion was re ­
quired: for probable aspergillosis, typical pulmonary infil­
trates on computed tomography scan of the thorax in combi­
nation with positive culture of sputum and/or broncho- 
alveolar lavage (BAL) fluid or eytological examination of 
BAl. fluid showing septate hyphae was necessary (16).
Statistical Analyses. Frequencies were analysed by the chi- 
square test. Nonparametrie tests were used for ordinal data: 
means were given along with their W5% confidence intervals, 
and p values below 5% were considered significant.
Results
Patients. 'Hie characteristics of the patients in the 
study are shown in Table l . ’IWenty-ninc patients 
received amphotericin B inhalations during one 
granulocytopenic period, seven (3 ALL. 4 AML) 
patients during Lvvo consecutive granulocytopen­
ic periods, and six (2 ALL. 4 AML) during three
episodes.
Tolerance o f  Amphotericin 11 Inhalations, Twenty- 
eight (67%) patients completed treatment at the 
full dose, although nine experienced side effects 
{'table 2). Another patient had no complaints and 
continued the regimen until he developed acute 
respiratory distress syndrome secondary to pneu­
monia. Of the remaining patients, three continued 
to inhale 10 mg t.i.d. until they developed severe 
progressive dyspnea necessitating a dose reduction 
to 5 mg t.i.d. One of these patients also developed 
a cough. Six (14%) other patients were able to tol­
erate only 5 mg t.i.d. because of dyspnea with signs 
of bronchial obstruction that were sufficiently se­
vere to prohibit a further increase in the dose of 
amphotericin B.The five (12%) remaining patients 
withdrew because of intolerable dyspnea and 
signs of severe bronchial obstruction and/or vom­
iting that developed immediately after inhaling the
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Table 2: Results with inhaled amphotericin B.
Treatment
completed
No. of 
patients
Side effects Action taken No. of 
patients
Mean dose 
(95% Cl)
No, with 
proven IPA
No. with 
probable IPA
Yes 28 no none 19 795 (713-920) 0
4
1
yes none 9 776 (581-988) 2 2
No 14 yes dose not escalated 6 736 (270-1123) 2 2
dose reduced 3 555 (185-1170) 1
treatment 5 1 1
discontinued
IPA, invasive pulmonary aspergillosis.
drug (2 patients at the dose of 1 mg amphotericin 
B, 2 at 3 mg, and 1 at 4 mg). Thus, 22 (52%) pa­
tients experienced side effects, only nine (41 %) of 
which were able to complete the full course of 
treatment. A high-pressure liquid chromatography 
assay of patient sera showed there was no sample 
with more than 0.1 mg/1 of amphotericin B,
Subjects experiencing side effects were 11.9 years 
(95% Cl, 0.9-25) older than those who had no 
complaints (mean age, 38 years; 95% Cl, 29-46) (p 
< 0.05) and had a mean age of 51 years (95% Cl,
42-60). Patients with a history of chronic obstruc­
tive pulmonary disease also tended to have a 
lower tolerance for inhalations (p = 0.09). How­
ever, there was no correlation between gender, 
haematologic disorder, type of selective gut decon­
tamination, or the total amount of amphotericin 
B inhaled and the development of side effects.
Efficacy o f Amphotericin B Inhalations. Twelve 
(28%) patients developed a proven or probable in­
vasive fungal infection. Histologic examination of 
lung tissue obtained at autopsy of four patients 
and from the sinus maxillaris tissue of another pa­
tient who survived the infection showed invading 
hyphae of a filamentous fungus; Aspergillus fumi- 
gatus was cultured in two cases. Two of these pa­
tients had tolerated the full dose of amphotericin Discussion 
B, two had been treated with 5 mg t.i.d., and one
patient stopped treatment because he could not Twenty-eight (67%) patients managed to complete 
tolerate it. Seven patients were designated as prophylacxic treatment with aerosolised ampho- 
having probable IPA; Aspergillus fumigatus was tericin B, although nine (32%) of them experi- 
recovered from BAL fluid in two cases and repeat- enced side effects. Thus, one-third of the patients 
edly from the sputa in a third case, while septate were unable to complete prophylaxis at the full 
hyphae were seen in BAL fluid in the remaining dose because coughing, signs of bronchial ob- 
four cases.Two of these patients had tolerated the struction, and nausea or vomiting occurred during 
full dose, three could tolerate only 5 mg t.i.d., and and immediately after inhalation. Tolerance was 
one stopped treatment because of intolerance. poorer amongst elderly patients and those who 
Three of these seven patients died with progres- had pre-existing signs of chronic pulmonary olv 
sive fungal infection despite extensive treatment, structive disease, possibly because the droplets in 
One patient who experienced no side effects dur- the aerosol contained a higher concentration of
ing treatment with the full dose developed prob­
able IPA and survived.
The development of proven or probable IPA was 
related to i) the presence of chronic obstructive 
lung disease (overall x = 6.37, p < 0.025; for prov­
en pulmonary aspergillosis x = 6.1, p < 0.025); ii) 
increasing age, with a difference of 11.9 years (p 
< 0.05; 95% CL 2-28); and iii) the occurrence of 
inhalation-related complaints (p < 0.05, x = 5.99). 
Rooms equipped with HEPA filters in combina­
tion with inhalation of amphotericin B may have 
offered better protection against IPA since there 
was one case of probable IPA during 18 courses 
in HEPA-equipped rooms compared with five 
proven and six probable cases of IPA during 43 
(25.6%) courses in regular rooms. However, 
there were not enough patients for this difference 
to reach significance ( p < 0.2,25.58 = 3,63, degrees 
of freedom = 2). The total dose of amphotericin 
B inhaled had no detectable impact on the occur­
rence of IPA, as mean total dose was 688 mg (95% 
CL 585-835 mg) in patients who developed IPA 
compared with 720 mg (95% CL 440-925 mg) in
those who did not.
Vol. 16. 1<W7 3 67
»
------------------------ - v _ « -------- — -------------  • .......................... ..............................i a . . ^ - _  . . .  „ ...................... ............ r f t . ^ TTr . _ .  -------- „ --------r,------ r r r >— I I. H ..J1  . I -T -n  ■ ■ ■  . . .  , - -  - . - w - ra
amphotericin B or desoxycholate than used in oth­
er studies (17), which can cause or aggravate 
bronchial obstruction (18). Others have reported 
lluit fewer side effects were associated with a na-
sal spray containing concentrations of amphoter­
icin B similar to that used bv us, concentrations
*
that seldom led to discontinuation of treatment (7, 
<Ml), Moreover, the occurrence of side effects 
showed no correlation with the total amount of 
amphotericin B inhaled.
Other studies have reported that inhalation of neb­
ulised amphotericin B is not well tolerated, 
Beyer et al. (12), who employed the same inhalation 
device as we did, noted that 23% of patients receiv­
ing 10 mg amphotericin B twice daily had to stop 
treatment prematurely because of coughing, a bad 
taste, or nausea but not because of bronchial ob­
struction. In a study by Gryn et al, (14), all patients 
complained of coughing and an unpleasant after­
taste, while (>y% experienced nausea and 17% de­
veloped wheezing. In another study bronchospasm 
affected one of 26 patients during inhalation (13), 
'Hie apparent differences in the incidence of side ef­
fects in these studies might be explained by the var­
ious aerosolising devices used (20).
Extensive experience with aerosolised pentami­
dine in AIDS patients suggests that it is rather dif­
ficult to predict side effects due to inhaled medi­
cation (21), Nonetheless, the degree of intolerance 
to inhaling nebulised amphotericin B is suffi­
ciently high to question its usefullness as prophy­
laxis. This form of prophylaxis does not appear ef­
fective in preventing IPA, since 12 (28.6%) pa­
tients in our study developed proven or probable 
IPA. Behre et al. (17) came to the same conclusion 
after performing an interim analysis of their ran­
domised study. Compliance does not appear to be 
the only factor responsible for these disappoint­
ing results, since there was no correlation be­
tween the incidence of IPA and the total amount 
of amphotericin B inhaled. Rather, the dose deliv­
ered at any one time might play a much more im­
portant role, Schmitt et ah (A) showed that ampho­
tericin B might protect rats infected experimental­
ly with Aspergillus spp, from developing disease, 
provided that the drug is delivered to the alveo­
lar space in a sufficient amount, However, a dose 
of 1.6 mg/kg of amphotericin B was required, 
which is equivalent to 112 mg for a 70 kg man or 
a dose tenfold higher than the one we used. Such 
a high dose is clearly out of the question* given the 
poor tolerance to 10 mg.
In conclusion, amphotericin B inhaled at a dose of
10 mg ta.d, is so poorly tolerated by granulocyto­
penic patients, particularly those most at risk of ac­
quiring IPA, such as the elderly and those with 
chronic obstructive pulmonary disease, that it has 
little to offer as a means of prophylaxis.
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